Page 12 - Herlev News Today

Healthtech startup Cerebriu partners with Danish hospital.

Evotec is an old player in the life sciences, but in offering new shares on the Nasdaq, the Germany-based company plans to bolster its new biologics manufacturing capabilities in the U.S and Europe. In other stock market debuts, IO Biotech’s IPO raised $100 million as it prepares a pivotal test of its lead cancer immunotherapy.

Also in todays EMEA regional roundup: Swedens Enea lands US traffic classification deal; Net Insight synchronizes 5G; why data center architecture rocks.

This multicenter randomized clinical trial compares the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia.

Increased use of analgesics linked to joint pain, need for improved symptom management, PsA Dx

Investegate announcements from LIDDS AB, NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy

Danish nurses continue wildcat stoppages in defiance of unions over pay and lack of staff, joined by sympathy strike of Silkeborg social workers; teachers across France walk out for 24 hours to demand more staff, better pay and conditions; Sunday pay strikes at ScotRail continue for over six months, 24-hour safety strikes continue at East Midlands Rail; Nigerian resident doctors on strike for nearly two months over pay arrears, while other health unions prevaricate about calling members out over...

Danish nurses defy union and Labour Court and continue one-hour strikes over pay and understaffing after ten-week strike ended; numerous strikes across healthcare system in France over pay and conditions; Sunday rail strikes continue UK’s longest pay dispute after re-ballot by conductors and ticket examiners; resident doctors’ strike in Nigeria in danger of sell-out after union suspends strike awaiting Labour court ruling

A broad education effort about cardiac arrest seemed to improve care and save lives, a...

The study found that people with the highest intakes of vitamin K1 were 21 percent less likely to be hospitalised with cardiovascular disease related to atherosclerosis. For vitamin K2, the risk of being hospitalised was 14 percent lower.